Biochemical markers of bone metabolism: An overview

Clinical Biochemistry

Volumn 30, Issue 8, 1997, Pages 573-593

  Christenson, Robert H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Alkaline phosphatase; Bone remodeling cycle; Bone specific alkaline phosphatase; C telopeptides; Calcium excretion; Hydroxyproline; N telopeptides; Osteoporosis; Procollagen extension peptides; Pyridinium crosslinks

Indexed keywords

ACID PHOSPHATASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CARBIMAZOLE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ESTROGEN; HYDROXYPROLINE; IODINE 125; OSTEOCALCIN; PAMIDRONIC ACID; PEPTIDE; PEPTIDE DERIVATIVE; PROCOLLAGEN; PYRIDINOLINE;

BONE METABOLISM; BONE METASTASIS; BONE MINERAL; CALCIUM URINE LEVEL; ENDOCRINE DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC DISORDER; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; CALCIUM; HUMANS; OSTEOCALCIN; OSTEOPOROSIS;

EID: 0031405795     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00113-6     Document Type: Review

References (134)

1. Delmas PD, Biochemical markers of bone turnover in osteoporosis. In: Osteoporosis: etiology, diagnosis and management. (Eds. Riggs VL, Metton LJ), Pp. 297-316. New York: Raven Press, 1988.
2. Eastell R, Delmas PD, Hodgson SF, et al. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Edocrinol Metab 1988; 67: 741-8.
3. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
4. Fujimoto D, Morigachi T, Ishida T, Hayaxhi H. The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun 1978; 84: 52-7.
5. Canalis E, Lorenzo J, Burgess WH, Maciag T. Effects of endothelial cell growth factor on bone remodeling in vitro. J Clin Invest 1987.
6. Abraham JA, Whang JL, Tumolo A, et al. Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J 1986; 5: 2523-8.
7. Frolik CA, Ellis LF, Williams DC. Isolation and characterization of insulin-like growth factor II from human bone. Biochem Biophys Res Commun 1988; 151: 1011-8.
8. Canalis E, Centrella M, McCarthy TL, Role of insulin-like growth factor I and II on skeletal remodeling. In: Molecular and cellular aspects of insulin and IGFI/IIL implications for the central nervous system. (Ed. Raizada MK)., Pp. 459-466. New York: Plenum, 1989.
9. Centrella M, Massague J, Canalis E. Human platelet-derived transforming growth factor-b stimulates parameters of bone growth in fetal rat calvarie. Endocrinology 1986; 119: 2306-12.
10. 1 and collagen type I. J Cell Biochem 1990; 44: 81-91.
11. Canalis E. Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat valvaria. Metabolism 1981; 30: 970-7.
12. Raisz LG, Martin TJ. Prostaglandins in bone and mineral metabolism. In: Bone and mineral research annual, vol 2. (Ed. Peck WA), Pp. 286. Amsterdam: Excerpta Medica, 1984.
13. 2. Prostaglandins 1984; 27: 97-103.
14. McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989; 124: 1247-53.
15. Horowitz MC, Coleman DL, Flood PM. Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. J Clin Invest 1988; 83: 149-57.
16. Schmidt-Gayk H, Bouillon R, Roth HJ. Measurement of vitamin D metabolites (calcidiol and calcitriol) and their clinical significance. Scand J Clin Lab Invest 1997; 57(Suppl 237): 35-45.
17. Canalis E, Regulation of bone remodeling. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (Ed. Favus MJ), Pp. 23-8. Richmond, VA: William Byrd Ress, 1990.
18. Civitelli R, Kim YS, Gunsten SL, et al. Nongenomic activation of the calcium message system by vitamin D metabolites in osteoblast-like cells. Endocrinology 1990; 127: 2253-62.
19. Takano-Yamamoto T, Rodan GA. Direct effects of 17b-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci USA 1990; 87: 2172-6.
20. Demers LM. Clinical usefulness of markers of bone degradation and formation. Scand J Clin Lab Invest 1997; 57(Suppl 237): 12-20.
21. Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33: 295-303.
22. Avioli LV. Calcitonin therapy for bone disease and hyperalcemia. Arch Intern Med 1982; 142: 2076-9.
23. Munk Nielson N, von der Recke P, Hansen MA, Overgaad K, Christiansen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calf Tissue Int 1994; 55: 8-11.
24. Canalis E, Regulation of bone remodeling. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2nd ed. (Ed. Favus MJ), Pp. 33-7. New York: Raven Press. 1993.
25. Martin TJ, Ng KW, Suda T. Bone cell physiology. Endocrinol Metab Clin North Am 1989; 18: 833-58.
26. Canalis E. Effects of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvarie. Endocrinology 1983; 112: 931-9.
27. Hanania NA, Chapman KR, Sturtidge WC, Szalai JP, Kesten S. Dose related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immuno 1995; 96: 571-9.
28. Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PM. Biochemical prediction of changes in spinal mae in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol 1993; 20: 1189-95.
29. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. WHO Technical Report Series No. 843, Geneva, World Health Organization, 1994.
30. Melton LJ III, Riggs BL, Clinical Spectrum. In: Osteoporosis: Etiology, Diagnosis, and Management. (Eds. BL Riggs, LJ Melton III), Pp. 155-79. New York: Raven Press, 1988.
31. Riggs BL. Overview of osteoporosis. West J Med 1991; 154: 63-77.
32. Albright F. Osteoporosis. Ann Intern Med 1947; 27: 861-82.
33. Riggs BL, Practical Management of the Patient with Osteoporosis. In: Osteoporosis: Etiology, Diagnosis, and Management. (Eds. BL Riggs, LJ Melton III), Pp. 481-90. New York: Raven Press, 1988.
34. Siebel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263-70.
35. Robbins SP, Turnover and Crosslinking of Collagen. In: Collagen in Health and Disease. (Eds. Weiss JB, Jayson MIV), Pp. 160-78. Edinburgh: Churchhill Livingston, 1982.
36. Risteli L, Risteli J. Biochemical markers of bone metabolism. Annal of Med 1993; 25: 385-93.
37. Christenson RH, Panigrahi K, Chapman JC, Silverman LM, Iosoenzymes and isoforms. In: Clinical Chemistry Theory, Analysis, Correlation. 3rd ed. (Eds. Kaplan LA, Pesce AJ), Pp. 1077-85. St. Louis: Mosby-Year Book, Inc., 1996.
38. Schiele F, Henny J, Hitz J, et al. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 1983; 29: 634-41.
39. Hill CS, Wolfert RL. The preparation of monoclonal antibodies that react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chem 1989; 186: 315-20.
40. Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocrine Reviews 1988; 9: 437-48.
41. Whyte MP. Alkaline phosphatase and the measurement of bone formation in clinical disorders of bone and mineral metabolism. In: Clinical Disorders of Bone and Mineral Metabolism. (Eds. Frame C, Potts JT, Jr), Pp. 108-11. Amsterdam: Excerpta Medica 1983.
42. Van Straalen JP, Sanders R, Prummel MF, Sanders GTB. Bone alkaline phosphatase as indicator of bone formation. Clin Chem Acta 1991; 201: 27-33.
43. Delmas P. Biochemical markers of bone turnover. Methodology and clinical use in osteoporosis. Am J Med 1991; 91 (suppl 5B): 59S-63S.
44. Duda RJ, O'Brien JF, Katzman JA, Peterson JM, Mann KG, Riggs BL. Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: effects of sex, age and metabolic bone disease. J Clin Endocrin Metab 1988; 66: 951-7.
45. Lindsay R. Sex seroids in the pathogenesis and prevention of osteoporosis. In: Osteoporosis: Etiology, Diagnosis, and Management. (Eds. Riggs L, Melton LJ), Pp. 333-58. New York: Raven Press, 1990.
46. Peck W. The pathogenesis of postmenopausal osteoporosis. In: Osteoporosis: Physiological Basis, Assessment and Treatment. (Eds. Deluca HF, Mazess R), Pp. 3-6. New York: Elsevier, 1990.
47. Devogalaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18: 141-50.
48. Van Hoof VO, Lapoutre LG, Hoylaerts MF, Chenvigne R, DeBroe ME. Improved agarose electroporesis method for separating alkaline phosphatase isoenzymes in serum. Clin Chem 1988; 34: 1657-62.
49. Rosalki SB, Foo AY. Two new methods for separating and quantifying bone and liver alkaline phosphatase. Clin Chem 1984; 30: 1182-6.
50. Moss DW. Alkaline phosphatase isoenzymes. Clin Chem 1982; 28: 2007-16.
51. Panigrahi K, Delmas PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994; 40: 822-8.
52. Gomez B, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41: 1560-6.
53. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 1489-94.
54. Liberman UA, Weiss SR, Broll, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
55. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrin Metab 1994; 79: 1693-700.
56. Overgaard K, Alexandersen P, Riis BJ, Christiansen C. Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. Clin Chem 1996; 10: 37-43.
57. Smodsrod B, Melkko B, Risteli L, Risteli J. Circulating carboxyterminal propeptide of type I procollagen is cleared via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345-50.
58. Taubman MB, Goldberg B, Sherr CJ. Radioimmunoassay for human procollagen. Science 1974; 186: 1115-7.
59. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-32.
60. Parfitt AM, Simon LS, Villanueva AR, Krane SK. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. Bone Miner Res 1987; 2: 427-36.
61. Rasmussen HB, Teisner B, Bangsgaard-Petersen F, Yde-Anderson E, Kassem M. Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts in nomal human serum and serum from patients with renal failure. Nephrol Dial Transplant 1992; 7: 902-7.
62. Eberling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-50.
63. Simons LS, Krane SM. Procollagen extension peptides as markers of collagen synthesis. In: Clinical disorders of bone and mineral metabolism. (Eds. Frame C, Potts JT, Jr.), Pp. 108-11. Amsterdam: Excerpta Medica 1983.
64. Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal peptide of type I collagen. Osteoporosis Int 1993; 3: 50-2.
65. Hassager C, Eriksen EF, Melkko J, Riselli L, Charles P, Mosekilde L, Ristelli J. Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J Bone Miner Res 1991; 6: 1295-1300.
66. Eberling PR, Peterson GM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7: 1243-50.
67. Fottrell PF, Power MJ. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991; 28: 287-335.
68. Price PA. Vitamin K-dependent bone protein. In: Calcium regulation and bone metabolism: basic and clinical aspects. (Eds. Cohn DV, Martin TJ, Meunier PJ), Pp. 419-26. Amsterdam: Elsevier, 1987.
69. Price PA, Williamson MK, Lothinger JW. Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 1981; 256: 12760-6.
70. Delmas PD, Wilson DM, Mann KG, et al. Effect of renal function on plasma levels of bone gla-protein. J Clin Endocrinol Metab 1983; 57: 1028-30.
71. Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocrin Pract 1996; 2: 13-19.
72. Brown JP, Delmas PD, Malaval L, Edouard MC, Chapuy MC, Meunier PJ. Serum bone gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 8386: 1091-3.
73. Charles P, Poser JW, Mosekilde L, Jenson FT. Estimation of bone turnover evaluated by 47 calcium kinetics: efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 1985; 76: 2254-8.
74. Bataille R, Delmas P, Sany J. Serum bone glaprotein in multiple myeloma. Cancer 1987; 59: 329-34.
75. Tracy RP, Andrianorivo A, Riggs BL, Mann KG. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation of assay results. Bone Miner Res 1990; 5: 451-61.
76. Power MJ, Fottrell PF. Solid phase enzymeimmunoassay for osteocalcin in human serum or plasma, with use of a monoclonal antibody. Clin Chem 1989; 35: 2087-92.
77. Monaghan DA, Power MJ, Fottrell PF. Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. Clin Chem 1993; 39: 942-7.
78. Colford J, Sailer D, Langham C. Five osteocalcin assays compared: tracer specificity, fragment interference, and calibration. Clin Chem 1997; 43: 1240-1.
79. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 92: 255-64.
80. Grundberg C, Weinstein RS. Multiple immunoreactive forms of bone gla-protein in uremic serum. J Clin Invest 1986; 77: 1762-7.
81. Kleerekoper M, Avioli LV. Evaluation and treatment of postmenopausal osteoporosis. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd ed. (Ed. Favus MJ), Pp. 223-9. New York: Raven Press, 1993.
82. Moss DW, Henderson AR. Enzymes. In: Tietz textbook of clinical chemistry. 2nd ed. (Eds. Burtis CA, Ashwood ER), Pp. 882-90. Philadelphia: W.B. Saunders Co., 1994.
83. Kraenzlin M, Lau KHW, Liang L. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990; 71: 442-51.
84. Stepan JJ, Pospichal J, Presl J, et al. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 1987; 8: 279-84.
85. Stepan JJ, Silinkova-Malkova E, Havrenek T, et al. Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983; 133: 189-200.
86. Piedra C, Torres R, Rapado A, et al. Serum tartrate resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 1989; 45: 58-60.
87. Prockop OJ, Kivirikko KI. Hydroxyproline and the metabolism of collagen. In: Treatise on metabolism of collagen. (Ed. Gould BS), Pp. 215-46. New York: Academic Press, 1987.
88. Kivrikko KI. Excretion of urinary hydroxyproline peptide in the assessment of bone collagen deposition and resorption. In: Clinical disorders of bone and mineral metabolism. (Eds. Frame B, Potts JT Jr), Pp. 105-7. Amsterdam: Excerpta Medica, 1983.
89. Lowry M, Hall DE, Brosnan JJ. Hydroxyproline metabolism in the rat kidney distribution of the renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine. Metabolism 1985; 39: 955.
90. Wilson PS, Kleerekoper M, Bone H, Parfitt AM. Urinary total hydroxyproline measured by HPLC: comparison of spot and timed urine collections. Clin Chem 1990; 36: 388-9.
91. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Min Res 1994; 9: 135-42.
92. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metabolism 1994; 79: 1693-700.
93. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-teopeptides of type 1 collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26-9.
94. Hanson DA, Weis MAE, Bollen A-M, Masian SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992; 7: 1251-8.
95. Campodarve I, Ulrich U, Bell N, et al. Urinary N-telopeptide of type I collagen monitors bone resorption and may predict change in bone mass of the spine in response to hormone replacement therapy. Bone Miner Res 1995; 10(Suppl 1): S182.
96. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43.
97. Siris E, Weinstein RS, Altaman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81: 961-7.
98. Marshall LA, Cain DF, Dmowski WP, Chesnut CH. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gyn 1996; 87: 350-4.
99. Risteli J, Elomaa I, Niemi S, Novamo A, Ristelli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40.
100. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994; 3: 780-5.
101. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. Bone Miner Res 1993; 8: 127-32.
102. Elomaa I, Virkkunen P, Ristelli L, Ristelli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Brit J Cancer 1992; 66: 337-41.
103. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Llomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993; 29a: 821-5.
104. Eyres KS, McCloskey EV, Fern ED, et al. Serum type I collagen carboxyterminal crosslinked telopeptide (S-1 CTP) in Paget's disease of bone and the effect of treatment with biphosphonates. Bone Miner 1992; 66: 337-41.
105. Hassager C, Jensen LT, Podenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decaoate and hormone replacement therapy. Calcif Tissue Int 1994; 54: 30-3.
106. Delmas PD. Biochemical markers for the assessment of bone turnover. In: Osteoporosis: etiology, diagnosis and management. 2nd ed. (Eds. Riggs VL, Metton LJ), Pp. 319-33. Philadelphia: Lippincott-Raven Publishers, 1995.
107. Seibel MJ, Robins Sp, Bilezikiau JP. Urinary pyridinium crosslinks of collagen. Trends Endocrinol Metab 1992; 3: 263-70.
108. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen. Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263-70.
109. James I, Crowley C, Perrett D. Assay of pyridinium crosslinks in serum using narrow-bone ion-paired reversed-phase high-performance liquid chromatography. J Chromatogr 1993; 612: 41-8.
110. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: the new marker for bone resorption. J Bone Miner Res 1993; 8: 635-41.
111. Eyre DR, Koob TJ, Van Ness KP. Quantitative of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 1984; 137: 380-8.
112. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988; 169: 197-203.
113. Field CS, Ory SJ, Wahner HW, Hermann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17b-estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial. Am J Obstes Gynecol 1993; 168: 114-21.
114. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endo Met 1991; 72: 367-73.
115. Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patient with vertebral osteoporosis. J Bone Miner Res 1991; 6(6): 639-44.
116. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991; 21: 310-5.
117. Delmas PD. Biochemical markers for the assessment of bone turnover. In: Osteoporosis: etiology, diagnosis, and management. (Eds. Riggs BL, Melton LH III), Pp. 319-33. Philadelphia: Lippincott-Raven Publishers, 1995.
118. Soletormos C, Schioler V, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprcision and biological variation. Clin Chem 1993; 10: 2077-83.
119. Blumsohn A, Hannon RA, Al-Dehaimi AW, Eastelli R. Short-term intraindividual variability of markers of bone turnover in healthy adults. J Bone Miner Res 1994; 9: S153.
120. Blumsohn A, Hannon RA, Al-Dehaimi AW, Eastell R. Short-term intraindividual variability of markers of bone turnover in healthy adults. J Bone Miner Res 1994; 9(Suppl. 1): S158.
121. Hannon RA. The use of biochemical markers to monitor skeletal response to hormone replacement therapy. Bone 1995; 16: 109S (abstract).
122. Boyd JC. Mathmatical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest 1997; 57(Suppl 237): 36-63.
123. Plebani M, Bernardi D, Zaninotto M, De Paoli M, Secchiero S, Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of skeletal metastasis. Clin Biochem 1996; 29: 67-72.
124. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996; 11: 1531-7.
125. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337-49.
126. Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 881-9.
127. Garnero P, Vassy V, Bertholin A, et al. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrin Metab 1994; 78: 955-9.
128. Fleisch H. Bisphosphonates. Drugs 1991; 42: 919-44.
129. Kanis JA, Gray RES. Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop 1987; 217: 99-125.
130. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26-9.
131. Rossini M, Gatti D, Zamberlan N, et al. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994; 9: 1833-7.
132. Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52.
133. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four year randomized study. Am J Med 1995; 99: 36-42.
134. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10: 641-9.